All data are based on the daily closing price as of October 22, 2025
e

EuBiologics

206650.KQ
9.09 USD
0.07
+0.78%

Overview

Last close
9.09 usd
Market cap
331.29M usd
52 week high
12.48 usd
52 week low
6.82 usd
Target price
10.48 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
4.9615
Price/Book Value
3.1106
Enterprise Value
304.03M usd
EV/Revenue
2.9266
EV/EBITDA
7.3349

Key financials

Revenue TTM
67.08M usd
Gross Profit TTM
67.08M usd
EBITDA TTM
11.78M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
137.10M usd
Net debt
N/A usd

About

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein vaccine under the rCRM197 name; and biopharmaceutical contract research and manufacturing, and contract testing services. Further, the company engages in the development of and support for the manufacturing technologies of biomedicines. The company was founded in 2010 and is headquartered in Seoul, South Korea.
  • Symbol
    206650.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://eubiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top